ATARA BIOTHERAPEUTICS, INC. Gain (Loss) on Sale of Properties
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Gain (Loss) on Sale of Properties of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:GainLossOnSaleOfProperties · last filed 2024-03-28
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for the quarter ending 2023-12-31 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for the quarter ending 2023-09-30 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for the quarter ending 2022-12-31 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for the quarter ending 2022-09-30 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for fiscal 2022 was $50.24M.
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for fiscal 2021 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. gain (loss) on sale of properties for fiscal 2020 was $0.00.
| Period end | Gain (Loss) on Sale of Properties 3 month | Gain (Loss) on Sale of Properties 6 month | Gain (Loss) on Sale of Properties 9 month | Gain (Loss) on Sale of Properties 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $50.24M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $50.24M 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | $50.24M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $0.00 derived: sum of 2 quarters · filed 2023-02-08 | $0.00 10-K · filed 2023-02-08 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |